Ipamorelin

5mg Vial

9 July 2026Updated 29 August 2026

Ipamorelin

Overview Research13 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for Ipamorelin.

Create free account Member login

Full range of benefits for Ipamorelin

Stimulates growth hormone (GH) release

Increases GH pulse amplitude and frequency

Can raise IGF-1 levels via GH-mediated pathways

Supports preservation and gain of lean muscle mass

May assist reduction of body fat and improve composition

Supports tissue repair and collagen synthesis

May promote bone formation via the GH/IGF‑1 axis

Selective GH stimulation with minimal cortisol/ACTH rise

May enhance recovery and exercise tolerance through GH effects

Can augment nocturnal GH secretion linked to sleep cycles

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(3)Compatible(4)Monitor(5)Avoid(4)

Generally well-tolerated alongside this peptide

Statins (HMG‑CoA reductase inhibitors)

No clinically significant pharmacokinetic interaction is expected between statins and ipamorelin, permitting routine co‑administration for lipid control.

ACE inhibitors / ARBs

Antihypertensive agents such as ACE inhibitors or ARBs have no known interaction with ipamorelin and are generally safe to continue.

Vitamin D and calcium supplements

Routine vitamin D and calcium supplementation does not meaningfully interact with ipamorelin therapy and requires no special adjustment.

Omega‑3 fatty acids (fish oil)

Omega‑3 supplementation has no known impact on ipamorelin pharmacology and is considered compatible for cardiovascular/metabolic support.

All interaction categories

Synergistic (3)

CJC-1295 (without DAC): Combining a GHRH analogue with ipamorelin (a GHSR agonist) produces a synergistic increase in pulsatile GH release and sustained IGF‑1 elevation compared with either agent alone.
Sermorelin (GHRH analogue): Concurrent GHRH stimulation via sermorelin and ghrelin‑receptor agonism by ipamorelin amplifies GH secretion amplitude and frequency, enhancing anabolic effects.
Testosterone (androgen therapy): Testosterone provides complementary anabolic effects and can augment muscle mass and strength gains when used with ipamorelin‑mediated GH/IGF‑1 stimulation.

Compatible (4)

Statins (HMG‑CoA reductase inhibitors): No clinically significant pharmacokinetic interaction is expected between statins and ipamorelin, permitting routine co‑administration for lipid control.
ACE inhibitors / ARBs: Antihypertensive agents such as ACE inhibitors or ARBs have no known interaction with ipamorelin and are generally safe to continue.
Vitamin D and calcium supplements: Routine vitamin D and calcium supplementation does not meaningfully interact with ipamorelin therapy and requires no special adjustment.
Omega‑3 fatty acids (fish oil): Omega‑3 supplementation has no known impact on ipamorelin pharmacology and is considered compatible for cardiovascular/metabolic support.

Monitor (5)

Insulin and oral hypoglycaemic agents (e.g., metformin, sulfonylureas): Because GH can induce insulin resistance and raise blood glucose, monitor glycaemic control and adjust antidiabetic dosing as needed during ipamorelin therapy.
Systemic glucocorticoids (e.g., prednisone): Exogenous corticosteroids blunt GH secretion and oppose metabolic actions of GH/IGF‑1, so monitor therapeutic response and consider dose/timing adjustments.
Thyroid hormone replacement (levothyroxine): Thyroid status influences the GH/IGF‑1 axis; monitor thyroid function tests and IGF‑1 because hypothyroidism can reduce and replacement can restore ipamorelin responsiveness.
Somatostatin analogues (octreotide, lanreotide): Somatostatin analogues suppress GH release and can attenuate ipamorelin efficacy, so monitor GH/IGF‑1 levels and clinical effect when co‑prescribed.
Recombinant human growth hormone (rhGH): Concurrent rhGH administration can produce additive increases in IGF‑1 and adverse effects (e.g., edema, glucose intolerance), requiring monitoring of IGF‑1 and side effects and dose reassessment.

Avoid (4)

Active malignancy or recent cancer history: Because elevated GH/IGF‑1 signaling may theoretically promote tumour growth, evaluate cancer risk and exercise caution before initiating ipamorelin in patients with active or recent malignancy.
Pregnancy and breastfeeding: Safety of ipamorelin in pregnancy and lactation is not established, so avoid use unless potential benefits justify potential risks and specialist input is obtained.
Uncontrolled diabetes mellitus: Patients with poorly controlled diabetes are at higher risk of worsening hyperglycaemia with GH secretagogues, so optimise glycaemic control prior to and during therapy.
Known pituitary adenoma or intracranial hypertension: Stimulating the GH axis may exacerbate mass‑effect symptoms or intracranial pressure, so assess pituitary status and obtain specialist endocrine/neurosurgical advice before treatment.